Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients

MH Nieuwenhuis, EMH Mathus-Vliegen, CG Baeten, FM Nagengast, J van der Bijl, AD van Dalsen, JH Kleibeuker, E (Erwin) Dekker, AM Langers, J Vecht, FT Peters, Remco Dam, WG van Gemert, WN Stuifbergen, Willem Rudolf Schouten, H Gelderblom, HFA Vasen

Research output: Contribution to journalArticleAcademicpeer-review

62 Citations (Scopus)
4 Downloads (Pure)


BACKGROUND: The optimal treatment of desmoid tumours is controversial. We evaluated desmoid management in Dutch familial adenomatous polyposis (FAP) patients. METHODS: Seventy-eight FAP patients with desmoids were identified from the Dutch Polyposis Registry. Data on desmoid morphology, management, and outcome were analysed retrospectively. Progression-free survival (PFS) rates and final outcome were compared for surgical vs non-surgical treatment, for intra-abdominal and extra-abdominal desmoids separately. Also, pharmacological treatment was evaluated for all desmoids. RESULTS: Median follow-up was 8 years. For intra-abdominal desmoids (n = 62), PFS rates at 10 years of follow-up were comparable after surgical and non-surgical treatment (33% and 49%, respectively, P = 0.163). None of these desmoids could be removed entirely. Eventually, one fifth died from desmoid disease. Most extra-abdominal and abdominal wall desmoids were treated surgically with a PFS rate of 63% and no deaths from desmoid disease. Comparison between NSAID and anti-estrogen treatment showed comparable outcomes. Four of the 10 patients who received chemotherapy had stabilisation of tumour growth, all after doxorubicin combination therapy. CONCLUSION: For intra-abdominal desmoids, a conservative approach and surgery showed comparable outcomes. For extra-abdominal and abdominal wall desmoids, surgery seemed appropriate. Different pharmacological therapies showed comparable outcomes. If chemotherapy was given for progressively growing intra-abdominal desmoids, most favourable outcomes occurred after combinations including doxorubicin. British Journal of Cancer (2011) 104, 37-42. doi:10.1038/sj.bjc.6605997 www.bjcancer.com Published online 9 November 2010 (C) 2011 Cancer Research UK
Original languageUndefined/Unknown
Pages (from-to)37-42
Number of pages6
JournalBritish Journal of Cancer
Issue number1
Publication statusPublished - 2011

Cite this